O. V. Knyazev

671 total citations
75 papers, 192 citations indexed

About

O. V. Knyazev is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, O. V. Knyazev has authored 75 papers receiving a total of 192 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Genetics, 38 papers in Epidemiology and 17 papers in Immunology. Recurrent topics in O. V. Knyazev's work include Inflammatory Bowel Disease (52 papers), Microscopic Colitis (31 papers) and Biomarkers in Disease Mechanisms (7 papers). O. V. Knyazev is often cited by papers focused on Inflammatory Bowel Disease (52 papers), Microscopic Colitis (31 papers) and Biomarkers in Disease Mechanisms (7 papers). O. V. Knyazev collaborates with scholars based in Russia, United States and Netherlands. O. V. Knyazev's co-authors include А И Парфенов, A Kagramanova, А. V. Veselov, М. В. Шапина, П. Л. Щербаков, Л. Б. Лазебник, Orlova Nv, Mikhail Konoplyannikov, И. Г. Бакулин and Владимир П. Баклаушев and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

O. V. Knyazev

61 papers receiving 176 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
O. V. Knyazev Russia	8	114	96	50	42	35	75	192
Ally Speight United Kingdom	7	45 0.4×	50 0.5×	35 0.7×	31 0.7×	20 0.6×	14	179
Zhihua Ran China	12	144 1.3×	98 1.0×	69 1.4×	64 1.5×	5 0.1×	27	278
T Feichtenschlager Austria	6	106 0.9×	87 0.9×	41 0.8×	21 0.5×	44 1.3×	14	218
Claire Liefferinckx Belgium	8	181 1.6×	136 1.4×	55 1.1×	83 2.0×	12 0.3×	23	230
Maxime Audet France	10	43 0.4×	56 0.6×	191 3.8×	20 0.5×	26 0.7×	15	290
Federico Zanzi Italy	7	89 0.8×	61 0.6×	41 0.8×	29 0.7×	8 0.2×	15	147
D. J. Buurman Netherlands	7	244 2.1×	157 1.6×	50 1.0×	154 3.7×	20 0.6×	8	338
Anneline Cremer Belgium	9	162 1.4×	129 1.3×	73 1.5×	54 1.3×	5 0.1×	21	219
Trond Espen Detlie Norway	7	101 0.9×	82 0.9×	32 0.6×	81 1.9×	33 0.9×	15	227
Wolfgang Mohl Germany	9	79 0.7×	64 0.7×	134 2.7×	18 0.4×	3 0.1×	32	229

Countries citing papers authored by O. V. Knyazev

Since Specialization

Citations

This map shows the geographic impact of O. V. Knyazev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. V. Knyazev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. V. Knyazev more than expected).

Fields of papers citing papers by O. V. Knyazev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. V. Knyazev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. V. Knyazev. The network helps show where O. V. Knyazev may publish in the future.

Co-authorship network of co-authors of O. V. Knyazev

This figure shows the co-authorship network connecting the top 25 collaborators of O. V. Knyazev. A scholar is included among the top collaborators of O. V. Knyazev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. V. Knyazev. O. V. Knyazev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Knyazev, O. V., et al.. (2024). The Experience of Using Ustekinumab in Bio-Naive Patients with Crohn's Disease with Unfavorable Prognosis Factors: Real Clinical Practice. Effective Pharmacotherapy. 20(2). 30–40.

Knyazev, O. V., et al.. (2023). THE ILLNESS PERCEPTION IN PATIENTS WITH INFLAMMATORY INTESTINAL DISEASES. 11(2). 165–174.

Knyazev, O. V., et al.. (2022). Efficacy and safety of ustekinumab therapy in patients with Crohn’s disease. Real clinical practice. Meditsinskiy sovet = Medical Council. 105–116. 1 indexed citations

Knyazev, O. V., et al.. (2022). S33 Alpha-1 Antitrypsin is a Marker of Increased Intestinal Permeability in Ulcerative Colitis and COVID-19 Infection. The American Journal of Gastroenterology. 117(12S). S9–S9. 1 indexed citations

Knyazev, O. V., et al.. (2022). Frequency and risk factors for thromboembolic complications in patients with inflammatory bowel diseases. Terapevticheskii arkhiv. 94(2). 172–179. 1 indexed citations

Шапина, М. В., et al.. (2021). Efficacy of tofacitinib as a «rescue therapy» in patients with severe ulcerative colitis. Koloproktologia. 20(3). 43–50. 2 indexed citations

Alexandrov, Tsviatko, et al.. (2021). Effect of cytomegalovirus infection on moderate and severe ulcerative colitis. Koloproktologia. 20(3). 28–34.

Knyazev, O. V., A Kagramanova, & А И Парфенов. (2021). Ulcerative colitis. To the 180th anniversary of the description by Karl Rokytansky. Terapevticheskii arkhiv. 93(12). 1564–1568. 1 indexed citations

Knyazev, O. V., et al.. (2020). Pharmacological and clinical feature of rebamipide: new therapeutic targets. SHILAP Revista de lepidopterología. 92(2). 104–111. 11 indexed citations

10.

Veselov, А. V., et al.. (2020). ECONOMIC BURDEN AND CURRENT STATUS OF THE DRUG SUPPLY MANAGEMENT FOR IMMUNE INFLAMMATORY DISEASES (BY EXAMPLE OF ULCERATIVE COLITIS AND CROHN’S DISEASE). Problems of Social Hygiene Public Health and History of Medicine. 28(Special Issue). 1137–1145. 6 indexed citations

11.

Knyazev, O. V., et al.. (2020). Stem Cell Therapy for Perianal Crohn’s Disease. Proceedings of the Latvian Academy of Sciences Section B Natural Exact and Applied Sciences. 74(2). 68–74. 1 indexed citations

12.

Knyazev, O. V., et al.. (2019). New options in management of Iron-Deficiency syndromes in Inflammatory Bowel Disease. Experimental and Clinical Gastroenterology. 162(2). 143–150. 2 indexed citations

13.

Belousova, E. А., И. Г. Бакулин, А. V. Veselov, et al.. (2019). EXPERIENCE OF TOFACITINIB USING IN THERAPY OF ULCERATIVE COLITIS IN REAL CLINICAL PRACTICE. Koloproktologia. 18(4). 86–99. 9 indexed citations

14.

Knyazev, O. V., et al.. (2019). O.V. Knyazev, A.V. Kagramanova, I.A. Korneeva, K.K. Noskova, S.V. Belousov, A.I. Parfenov. SHILAP Revista de lepidopterología. 91(4). 53–61. 6 indexed citations

15.

Knyazev, O. V., et al.. (2018). Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice. Terapevticheskii arkhiv. 90(6). 74–80. 3 indexed citations

16.

Knyazev, O. V. & A Kagramanova. (2017). THE RESULTS OF THE USE OF 5-AMINOSALICYLIC ACID AS AN ANTI-RELAPSE AND MAINTENANCE THERAPY ULCERATIVE COLITIS MODERATE SEVERITY IN CLINICAL PRACTICE. Meditsinskiy sovet = Medical Council. 108–117. 1 indexed citations

17.

Knyazev, O. V., et al.. (2016). P526. Sampling not at trough: adalimumab serum drug and antibody levels remain relatively stable in between injections. Journal of Crohn s and Colitis. 10(suppl 1). S367.2–S368. 2 indexed citations

18.

Kagramanova, A, et al.. (2016). P-068 The Combined of Mesenchymal Stem Cells and Anticytokine Therapy Reduces the Recurrence Rate of Crohnʼs Disease. Inflammatory Bowel Diseases. 22. S31–S31. 1 indexed citations

19.

Лазебник, Л. Б., et al.. (2011). [The immune status changes in patients with inflammatory bowel disease under the influence of mesenchymal stromal cells and infliximab therapy].. PubMed. 11–7. 1 indexed citations

20.

Лазебник, Л. Б., et al.. (2011). Optimizing cell therapy in patients with Ulcerative Colitis. Inflammatory Bowel Diseases. 17. S49–S49.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact